Htay Htay1, Aminu K Bello2, Adeera Levin3, Meaghan Lunney4, Mohamed A Osman2, Feng Ye2, Gloria E Ashuntantang5, Ezequiel Bellorin-Font6, Mohammed Benghanem Gharbi7, Sara N Davison2, Mohammad Ghnaimat8, Paul Harden9, Vivekanand Jha10, Kamyar Kalantar-Zadeh11, Peter G Kerr12, Scott Klarenbach2, Csaba P Kovesdy13, Valerie A Luyckx14, Brendon Neuen15, Donal O'Donoghue16, Shahrzad Ossareh17, Jeffrey Perl18, Harun Ur Rashid19, Eric Rondeau20, Emily J See21, Syed Saad2, Laura Sola22, Irma Tchokhonelidze23, Vladimir Tesar24, Kriang Tungsanga25, Rumeyza Turan Kazancioglu26, Angela Yee-Moon Wang27, Chih-Wei Yang28, Alexander Zemchenkov29, Ming-Hui Zhao30, Kitty J Jager31, Fergus J Caskey32, Vlado Perkovic33, Kailash K Jindal2, Ikechi G Okpechi34, Marcello Tonelli35, David C Harris36, David W Johnson37. 1. Department of Renal Medicine, Singapore General Hospital, Singapore. 2. Division of Nephrology and Immunology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. 3. Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 4. Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada. 5. Faculty of Medicine and Biomedical Sciences, Yaounde General Hospital, University of Yaounde I, Yaounde, Cameroon. 6. Division of Nephology and Hypertension, Department of Medicine, Saint Louis University, Saint Louis, MO. 7. Urinary Tract Diseases Department, Faculty of Medicine and Pharmacy of Casablanca, University Hassan II of Casablanca, Casablanca, Morocco. 8. Nephrology Division, Department of Internal Medicine, The Specialty Hospital, Amman, Jordan. 9. Oxford Kidney Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. 10. George Institute for Global Health, UNSW, New Delhi; Manipal Academy of Higher Education, Manipal, India; School of Public Health, Imperial College, London, United Kingdom. 11. Division of Nephrology and Hypertension and Kidney Transplantation, University of California Irvine Medical Center, Orange, CA. 12. Department of Nephrology, Monash Medical Centre, Monash Health, Clayton, Victoria, Australia; Department of Medicine, Monash University, Clayton, Victoria, Australia. 13. University of Tennessee Health Science Center, Memphis, TN. 14. Institute of Biomedical Ethics and the History of Medicine, University of Zurich, Zurich, Switzerland; Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 15. The George Institute for Global Health, Newtown, New South Wales, Australia. 16. Salford Royal NHS Foundation Trust, Salford; University of Manchester, Manchester, United Kingdom. 17. Division of Nephrology, Department of Medicine, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran. 18. Division of Nephrology, St. Michael's Hospital and the Keenan Research Centre in the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada; Division of Nephrology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 19. Department of Nephrology, Kidney Foundation Hospital and Research Institute, Dhaka, Bangladesh. 20. Intensive Care Nephrology and Transplantation Department, Hopital Tenon, Assistance Publique-Hopitaux de Paris, Paris, France; Sorbonne Université, Paris, France. 21. Department of Intensive Care, Austin Health, Melbourne, Australia; School of Medicine, University of Melbourne, Melbourne, Australia. 22. Dialysis Unit, CASMU-IAMPP, Montevideo, Uruguay. 23. Nephrology Development Clinical Center, Tbilisi State Medical University, Tbilisi, Georgia. 24. Department of Nephrology, General University Hospital, Charles University, Prague, Czech Republic. 25. Department of Medicine, Faculty of Medicine, King Chulalong Memorial Hospital, Chulalongkorn University, Bangkok, Thailand; Bhumirajanagarindra Kidney Institute, Bangkok, Thailand. 26. Division of Nephrology, Bezmialem Vakif University, Istanbul, Turkey. 27. Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong. 28. Kidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan. 29. Department of Internal Disease, Clinical Pharmacology and Nephrology, North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia; Department of Nephrology and Dialysis, Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia. 30. Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China; Key Lab of Renal Disease, Ministry of Health of China, Beijing, China; Key Lab of Chronic Kidney Disease Prevention and Treatment, Ministry of Education of China, Beijing, China; Peking-Tsinghua Center for Life Sciences, Beijing, China. 31. ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, Amsterdam Public Health Research Institute, University of Amsterdam, Amsterdam, the Netherlands. 32. Population Health Sciences, University of Bristol, Bristol, United Kingdom; Renal Unit, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom. 33. The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia. 34. Division of Nephrology and Immunology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; Division of Nephrology and Hypertension, University of Cape Town, Cape Town, South Africa; Kidney and Hypertension Research Unit, University of Cape Town, Cape Town, South Africa. 35. Department of Medicine, University of Calgary, Calgary, Alberta, Canada; Pan-American Health Organization/World Health Organization's Collaborating Centre in Prevention and Control of Chronic Kidney DiseaseUniversity of Calgary, Calgary, Alberta, Canada. 36. Centre for Transplantation and Renal Research, Westmead Institute for Medical Research, University of Sydney, Sydney, New South Wales. 37. Centre for Kidney Disease Research, University of Queensland, Brisbane, Australia; Translational Research Institute, Brisbane, Australia; Metro South and Ipswich Nephrology and Transplant Services (MINTS), Princess Alexandra Hospital, Brisbane, Australia. Electronic address: david.johnson2@health.qld.gov.au.
Abstract
RATIONALE & OBJECTIVE: Hemodialysis (HD) is the most common form of kidney replacement therapy. This study aimed to examine the use, availability, accessibility, affordability, and quality of HD care worldwide. STUDY DESIGN: A cross-sectional survey. SETTING & PARTICIPANTS: Stakeholders (clinicians, policy makers, and consumer representatives) in 182 countries were convened by the International Society of Nephrology from July to September 2018. OUTCOMES: Use, availability, accessibility, affordability, and quality of HD care. ANALYTICAL APPROACH: Descriptive statistics. RESULTS: Overall, representatives from 160 (88%) countries participated. Median country-specific use of maintenance HD was 298.4 (IQR, 80.5-599.4) per million population (pmp). Global median HD use among incident patients with kidney failure was 98.0 (IQR, 81.5-140.8) pmp and median number of HD centers was 4.5 (IQR, 1.2-9.9) pmp. Adequate HD services (3-4 hours 3 times weekly) were generally available in 27% of low-income countries. Home HD was generally available in 36% of high-income countries. 32% of countries performed monitoring of patient-reported outcomes; 61%, monitoring of small-solute clearance; 60%, monitoring of bone mineral markers; 51%, monitoring of technique survival; and 60%, monitoring of patient survival. At initiation of maintenance dialysis, only 5% of countries used an arteriovenous access in almost all patients. Vascular access education was suboptimal, funding for vascular access procedures was not uniform, and copayments were greater in countries with lower levels of income. Patients in 23% of the low-income countries had to pay >75% of HD costs compared with patients in only 4% of high-income countries. LIMITATIONS: A cross-sectional survey with possibility of response bias, social desirability bias, and limited data collection preventing in-depth analysis. CONCLUSIONS: In summary, findings reveal substantial variations in global HD use, availability, accessibility, quality, and affordability worldwide, with the lowest use evident in low- and lower-middle-income countries. Crown
RATIONALE & OBJECTIVE: Hemodialysis (HD) is the most common form of kidney replacement therapy. This study aimed to examine the use, availability, accessibility, affordability, and quality of HD care worldwide. STUDY DESIGN: A cross-sectional survey. SETTING & PARTICIPANTS: Stakeholders (clinicians, policy makers, and consumer representatives) in 182 countries were convened by the International Society of Nephrology from July to September 2018. OUTCOMES: Use, availability, accessibility, affordability, and quality of HD care. ANALYTICAL APPROACH: Descriptive statistics. RESULTS: Overall, representatives from 160 (88%) countries participated. Median country-specific use of maintenance HD was 298.4 (IQR, 80.5-599.4) per million population (pmp). Global median HD use among incident patients with kidney failure was 98.0 (IQR, 81.5-140.8) pmp and median number of HD centers was 4.5 (IQR, 1.2-9.9) pmp. Adequate HD services (3-4 hours 3 times weekly) were generally available in 27% of low-income countries. Home HD was generally available in 36% of high-income countries. 32% of countries performed monitoring of patient-reported outcomes; 61%, monitoring of small-solute clearance; 60%, monitoring of bone mineral markers; 51%, monitoring of technique survival; and 60%, monitoring of patient survival. At initiation of maintenance dialysis, only 5% of countries used an arteriovenous access in almost all patients. Vascular access education was suboptimal, funding for vascular access procedures was not uniform, and copayments were greater in countries with lower levels of income. Patients in 23% of the low-income countries had to pay >75% of HD costs compared with patients in only 4% of high-income countries. LIMITATIONS: A cross-sectional survey with possibility of response bias, social desirability bias, and limited data collection preventing in-depth analysis. CONCLUSIONS: In summary, findings reveal substantial variations in global HD use, availability, accessibility, quality, and affordability worldwide, with the lowest use evident in low- and lower-middle-income countries. Crown
Keywords:
ESKD care; HD accessibility; HD affordability; HD availability; Hemodialysis (HD); RRT modality; end-stage kidney disease (ESKD); funding for HD services; global survey; health care delivery; health care disparities; health policy; international differences; kidney failure; quality of HD services; renal replacement therapy (RRT)
Authors: Aminu K Bello; Ikechi G Okpechi; Mohamed A Osman; Yeoungjee Cho; Htay Htay; Vivekanand Jha; Marina Wainstein; David W Johnson Journal: Nat Rev Nephrol Date: 2022-02-22 Impact factor: 42.439